http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Top 10 News for 9/19 - 9/23: Twitter on the Auction Block; Allergan Bolsters NASH Effort; Microsoft Returns Value
-
CFO Darryl Button to Leave Aegon
-
Aegon Appoints Global Head of Government and Policy Affairs
-
FTC: Teva (TEVA) Agrees to Divest 79 Pharma Products to Settle Actavis (AGN) Generics Merger Issues
-
Amgen (AMGN), Allergan (AGN) Announce Results from ABP 980 Phase 3 in HER2+ Breast Cancer; Superiority Not Ruled Out
-
Amgen And Allergan Announce Top-Line Results From Phase 3 Study Evaluating ABP 980 Compared With Trastuzumab In Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer
-
Allergan Reaches Out To Family Caregivers Of People With Alzheimer's Disease With New PSA, Website
-
Allergan (AGN), Ironwood Pharma's (IRWD) Linaclotide sNDA Accepted for Review by U.S. FDA
-
Ironwood and Allergan Announce Supplemental New Drug Application for 72 mcg Linaclotide in Chronic Idiopathic Constipation Has Been Accepted for FDA Review
-
The Allergan Foundation And The Jed Foundation Announce Three-Year $300,000 Scholarship Fund To Support JED Campus Program
-
UPDATE: Valeant Pharma (VRX) Said Actively Discussing Sale of Bausch + Lomb Unit
-
Pfizer (PFE) Announces Termination of Merger Agreement with Allergan (AGN)
-
Pfizer Announces Termination of Proposed Combination with Allergan
-
Pre-Open Stock Movers 04/05: (VRX) (MRVL) (ICPT) Higher; (PSUN) (AGN) (NATI) Lower (more...)
-
Pfizer (PFE), Allergan (AGN) Announce Receipt of FTC Request for Additional Info on Proposed Merger
-
Pfizer and Allergan Receive Request for Additional Information from Federal Trade Commission Regarding Proposed Combination
-
Independent Baylor University Study Showcases Economic Impact of Allergan on Waco and Central Texas Economies
-
Workers' Vision of a Flexible Retirement Requires Support From Employers
-
Ironwood and Allergan Initiate Phase IIb Clinical Trial of Linaclotide Colonic Release in Adults with Irritable Bowel Syndrome with Constipation
-
Allergan Acquires Rights To Ironwood's CONSTELLA® (Linaclotide) From Almirall In More Than 40 Countries
-
Controversial pharma CEO Martin Shkreli bails on Valeant bet
-
Amgen And Allergan Announce Positive Top-line Results From Phase 3 Study of Biosimilar Candidate ABP 215
-
Biotechs Pressured Following Clinton Tweet (IBB)
-
Allergan Supports World Alzheimer's Disease Day by Giving Back
-
New Campaign Thanks Caregivers of People with Alzheimer's Disease
-
Homemakers Are Not Off the Hook in Terms of Saving and Planning for Retirement
-
ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health
-
Top 10 News for 7/27 - 7/31: Teva Makes it Official with Allergan; China Stock Slide Continues; Revised Q2 GDP Misses Mark
-
Transamerica Supports Two Athletes in the 2015 Special Olympics World Games
-
Allergan Enters Into Licensing Agreement with Merck to Obtain Exclusive Worldwide Rights to CGRP Migraine Development Program
-
StreetInsider Top 50 Takeover Targets Notable Changes: (KYTH) (TMUS) (RCPT) (SGYP) (TWTR)
-
How Can We Inspire a World of Habitual Retirement Savers?
-
Top 10 News for 10/27 - 10/31: Fed Ends Easing; Q3 was Tough on Social Media Giants; Apple CEO Cook Gets Personal
-
Market Wrap: Valeant Lifts Allergan Bid; Twitter's Ho-Hum Q3 Report; Tesla Slumps on Sales Speculation
-
Allergan (AGN) Near Deal to Acquire Salix Pharma (SLXP) - CNBC's Faber
-
Top 10 News for 05/27 - 05/30: Hillshire's Bidding War; Apple's Got the 'Beats'; More Love for Twitter
-
Market Wrap: Apple's Big Deal; Valeant Sweetens Allergan Offer; Another Solid Kors Quarter
-
Trading Radar for 02/05: Disney (DIS), Time Warner (TWX), Humana (HUM), Green Mountain (GMCR), Pandora (P) Report
-
Wall Street Hubbub 7/14: iPhone 4 Recall, Penthouse-for-Playboy, BP's New Cap Is No Savior, KKR IPO, Treasury Weighs Citi (C) Options

